News · 26 weeks70-36%
2026-03-012026-08-23
Mix3090d
- Insider14(47%)
- Other7(23%)
- SEC Filings4(13%)
- Analyst2(7%)
- Earnings2(7%)
- Leadership1(3%)
Latest news
25 items- INSIDERNew insider Saccaro James claimed no ownership of stock in the company (SEC Form 3)3 - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and PuppiesExpands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living
- INSIDERDirector Damelio Frank A gifted 6,650 shares, decreasing direct ownership by 31% to 14,808 units (SEC Form 4)4 - Zoetis Inc. (0001555280) (Issuer)
- SECSEC Form 8-K filed by Zoetis Inc.8-K - Zoetis Inc. (0001555280) (Filer)
- SECSEC Form 10-Q filed by Zoetis Inc.10-Q - Zoetis Inc. (0001555280) (Filer)
- ANALYSTZoetis downgraded by William BlairWilliam Blair downgraded Zoetis from Outperform to Mkt Perform
- SECZoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Zoetis Inc. (0001555280) (Filer)
- PRZoetis Announces Second Quarter 2026 ResultsRevenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis Adjusted Net Income of $781 Million, or Adjusted Diluted EPS of $1.87 Revenue and Adjusted Net Income Declined 1% and 2%, Respectively, on an Organic Operational Basis Revises Full Year 2026 Revenue Guidance to $9.120 - $9.320 Billion to Organic Operational Revenue Growth of (3)% to (1)% Revises Full Year 2026 Adjusted Net Income Guidance to Organic Operational Growth of (9)% to (5)% Revises Guidance for Adjusted Diluted EPS to $6.15 - $6.25 Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today repor
- PRZoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating OfficerSaccaro’s Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027 Zoetis Inc. (NYSE:ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With Mr. Saccaro’s appointment, Wetteny Joseph will transition to an advisory role effective
- PRZoetis Launches Portela® (relfovetmab) in Canada and the European UnionFirst long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. Backed by nearly a decade of science and research, Portela demonstrated effectiveness in alleviating OA pain in a pivotal nine-month European field study with improvements observed from a
- PRZoetis Launches Lenivia® (izenivetmab injection) in Canada and the European UnionUp to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection Zoetis Inc. (NYSE:ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study, with effects observed from as early as Day 7 aft
- INSIDERSEC Form 4 filed by Executive Vice President Sarbaugh Keith4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Peck Kristin C4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Esch Kevin4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Nayak Abhay U4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Driscoll Rimma4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Fuller Julie4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Lagano Roxanne4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Executive Vice President Ferran Astorga Jeannette4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Joseph Wetteny4 - Zoetis Inc. (0001555280) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Nayak Abhay U3/A - Zoetis Inc. (0001555280) (Issuer)
- PRZoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic CapabilitiesAcquisition would strengthen Zoetis’ Global Diagnostics portfolio through teleradiology, imaging services, and workflow technology, advancing a more comprehensive end-to-end Virtual Reference Lab Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisition adds around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. Integrating VitalRADS’ capabilities into Zoetis’ Global Diagnostics portfolio enhances Zoetis’ reference laboratory services, delivering AI-assisted report generation and quali
- PRZoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-NDRecombinant vector vaccine protects chickens against Newcastle disease and Marek's disease in a single dose Zoetis Inc. (NYSE:ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease (ND) and Marek’s disease viruses. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both diseases with a single dose. Newcastle disease is a notifiable disease under EU animal health regulations and a significant cause of mortality and production losses in commercial poultry, as evidenced by rece
- PRZoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial ResultsZoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, August 6, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on August 6, 2026. About Zoetis Zoetis is the world’s leading animal health company, driven by a singular purpose: to
- INSIDERSEC Form 4 filed by Director Stetter Mark4 - Zoetis Inc. (0001555280) (Issuer)
ZTS FAQ
7 questionsWhat does Zoetis Inc. do?
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria...Where does ZTS stock trade?
Zoetis Inc. (ZTS) is listed on NYSE.What sector and industry is ZTS in?
Zoetis Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zoetis Inc. go public?
Zoetis Inc. (ZTS) completed its IPO in 2013.What are analysts saying about ZTS?
Zoetis Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2026-08-06.What companies are similar to ZTS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ZTS side-by-side with any of them on Quantisnow.How can I track ZTS on Quantisnow?
Quantisnow aggregates Zoetis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZTS to receive live email and push alerts on every new disclosure.